NervGen Pharma Correlations
| NGENF Stock | USD 2.03 0.03 1.50% |
The current 90-days correlation between NervGen Pharma Corp and Elevation Oncology is 0.19 (i.e., Average diversification). The correlation of NervGen Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
NervGen Pharma Correlation With Market
Average diversification
The correlation between NervGen Pharma Corp and DJI is 0.14 (i.e., Average diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding NervGen Pharma Corp and DJI in the same portfolio, assuming nothing else is changed.
NervGen |
The ability to find closely correlated positions to NervGen Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace NervGen Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back NervGen Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling NervGen Pharma Corp to buy it.
Moving together with NervGen OTC Stock
Moving against NervGen OTC Stock
| 0.42 | BMA | Banco Macro SA | PairCorr |
| 0.36 | PLTR | Palantir Technologies Aggressive Push | PairCorr |
| 0.33 | KAKZF | Kaspi Bank Joint | PairCorr |
| 0.52 | AA | Alcoa Corp Fiscal Year End 15th of January 2025 | PairCorr |
| 0.47 | T | ATT Inc Fiscal Year End 22nd of January 2025 | PairCorr |
| 0.45 | HD | Home Depot | PairCorr |
| 0.42 | HPQ | HP Inc | PairCorr |
| 0.41 | INTC | Intel Fiscal Year End 23rd of January 2025 | PairCorr |
| 0.4 | CVX | Chevron Corp Sell-off Trend | PairCorr |
| 0.39 | TRV | The Travelers Companies Fiscal Year End 17th of January 2025 | PairCorr |
| 0.34 | IBM | International Business Fiscal Year End 22nd of January 2025 | PairCorr |
| 0.33 | DIS | Walt Disney Sell-off Trend | PairCorr |
Related Correlations Analysis
| -0.59 | 0.78 | -0.43 | 0.05 | RIGL | ||
| -0.59 | -0.66 | 0.61 | 0.25 | GERN | ||
| 0.78 | -0.66 | -0.7 | -0.09 | VSTM | ||
| -0.43 | 0.61 | -0.7 | 0.46 | IMMP | ||
| 0.05 | 0.25 | -0.09 | 0.46 | ELEV | ||
| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between NervGen OTC Stock performing well and NervGen Pharma OTC Stock doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze NervGen Pharma's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| RIGL | 3.41 | 1.06 | 0.37 | 0.63 | 2.40 | 9.10 | 55.18 | |||
| GERN | 2.21 | (0.24) | 0.00 | (0.10) | 0.00 | 4.17 | 14.00 | |||
| VSTM | 4.31 | 1.25 | 0.23 | 1.41 | 4.51 | 12.84 | 31.27 | |||
| IMMP | 2.39 | (0.35) | 0.00 | (0.43) | 0.00 | 4.89 | 18.55 | |||
| ELEV | 3.46 | (0.37) | 0.00 | (0.05) | 0.00 | 5.77 | 22.21 |
Be your own money manager
Our tools can tell you how much better you can do entering a position in NervGen Pharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Manager Now
Portfolio ManagerState of the art Portfolio Manager to monitor and improve performance of your invested capital |
| All Next | Launch Module |
NervGen Pharma Corporate Management
Elected by the shareholders, the NervGen Pharma's board of directors comprises two types of representatives: NervGen Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of NervGen. The board's role is to monitor NervGen Pharma's management team and ensure that shareholders' interests are well served. NervGen Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, NervGen Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Brian McAlister | CoFounder Advisor | Profile | |
| Harold DMD | CoFounder Director | Profile | |
| Adam MD | Interim Director | Profile | |
| William BASc | Interim CoFounder | Profile |